Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer

Author:

Camidge D. Ross1,Kim Hye Ryun1,Ahn Myung-Ju1,Yang James Chih-Hsin1,Han Ji-Youn1,Lee Jong-Seok1,Hochmair Maximilian J.1,Li Jacky Yu-Chung1,Chang Gee-Chen1,Lee Ki Hyeong1,Gridelli Cesare1,Delmonte Angelo1,Garcia Campelo Rosario1,Kim Dong-Wan1,Bearz Alessandra1,Griesinger Frank1,Morabito Alessandro1,Felip Enriqueta1,Califano Raffaele1,Ghosh Sharmistha1,Spira Alexander1,Gettinger Scott N.1,Tiseo Marcello1,Gupta Neeraj1,Haney Jeff1,Kerstein David1,Popat Sanjay1

Affiliation:

1. From the University of Colorado Cancer Center, Aurora (D.R.C.); Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine (H.R.K.), Samsung Medical Center (M.-J.A.), and Seoul National University Hospital (D.-W.K.), Seoul, National Cancer Center, Goyang (J.-Y.H.), Seoul National University Bundang Hospital, Seongnam (J.-S.L.), and Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju (K.H.L.) —...

Funder

ARIAD Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Publisher

Massachusetts Medical Society

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3